These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 9354452)
1. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Huang A; Fan H; Taylor WR; Wright JA Cancer Res; 1997 Nov; 57(21):4876-81. PubMed ID: 9354452 [TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification. Huang A; Wright JA Oncogene; 1994 Feb; 9(2):491-9. PubMed ID: 7904743 [TBL] [Abstract][Full Text] [Related]
3. Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression. Huang A; Jin H; Wright JA Cancer Res; 1995 Apr; 55(8):1758-62. PubMed ID: 7712485 [TBL] [Abstract][Full Text] [Related]
4. A link between ferritin gene expression and ribonucleotide reductase R2 protein, as demonstrated by retroviral vector mediated stable expression of R2 cDNA. Fan H; Villegas C; Wright JA FEBS Lett; 1996 Mar; 382(1-2):145-8. PubMed ID: 8612737 [TBL] [Abstract][Full Text] [Related]
5. Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells. Wani MA; Xu X; Stambrook PJ Cancer Res; 1994 May; 54(9):2504-8. PubMed ID: 8162600 [TBL] [Abstract][Full Text] [Related]
7. Alterations in the cyclic AMP signal transduction pathway regulating ribonucleotide reductase gene expression in malignant H-ras transformed cell lines. Hurta RA; Wright JA J Cell Physiol; 1994 Jan; 158(1):187-97. PubMed ID: 7505277 [TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Fan H; Villegas C; Wright JA Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14036-40. PubMed ID: 8943056 [TBL] [Abstract][Full Text] [Related]
9. Inefficient growth arrest in response to dNTP starvation stimulates gene amplification through bridge-breakage-fusion cycles. Poupon MF; Smith KA; Chernova OB; Gilbert C; Stark GR Mol Biol Cell; 1996 Mar; 7(3):345-54. PubMed ID: 8868464 [TBL] [Abstract][Full Text] [Related]
10. Altered regulation of message stability and tumor promoter-responsive cis-trans interactions of ribonucleotide reductase R1 and R2 messenger RNAs in hydroxyurea-resistant cells. Amara FM; Hurta RA; Huang A; Wright JA Cancer Res; 1995 Oct; 55(20):4503-6. PubMed ID: 7553616 [TBL] [Abstract][Full Text] [Related]
11. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Fan H; Villegas C; Huang A; Wright JA Cancer Res; 1998 Apr; 58(8):1650-3. PubMed ID: 9563477 [TBL] [Abstract][Full Text] [Related]
12. Multiple effects on drug-sensitivity, genome stability and malignant potential by combinations of h-ras, C-myc and mutant p53 gene overexpression. Huang A; Jin H; Taylor W; Wright J Int J Oncol; 1995 Jul; 7(1):57-63. PubMed ID: 21552806 [TBL] [Abstract][Full Text] [Related]
13. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. Lin ZP; Belcourt MF; Cory JG; Sartorelli AC J Biol Chem; 2004 Jun; 279(26):27030-8. PubMed ID: 15096505 [TBL] [Abstract][Full Text] [Related]
15. Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Paulson TG; Almasan A; Brody LL; Wahl GM Mol Cell Biol; 1998 May; 18(5):3089-100. PubMed ID: 9566927 [TBL] [Abstract][Full Text] [Related]
16. Correlation of genetic instability and apoptosis in the presence of oncogenic Ki-Ras. Chen CY; Liou J; Forman LW; Faller DV Cell Death Differ; 1998 Nov; 5(11):984-95. PubMed ID: 9846185 [TBL] [Abstract][Full Text] [Related]
17. Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit. Ask A; Persson L; Rehnholm A; Frostesjö L; Holm I; Heby O Cancer Res; 1993 Nov; 53(21):5262-8. PubMed ID: 8221660 [TBL] [Abstract][Full Text] [Related]
18. Apoptosis induced by inhibitors of nucleotide synthesis in deoxyadenosine-resistant leukemia L1210 cells that lack p53 expression. Cory AH; Hickerson DH; Cory JG Anticancer Res; 2000; 20(6B):4171-8. PubMed ID: 11205244 [TBL] [Abstract][Full Text] [Related]
19. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. El-Hizawi S; Lagowski JP; Kulesz-Martin M; Albor A Cancer Res; 2002 Jun; 62(11):3264-70. PubMed ID: 12036943 [TBL] [Abstract][Full Text] [Related]
20. Correlation between levels of ferritin and the iron-containing component of ribonucleotide reductase in hydroxyurea-sensitive, -resistant, and -revertant cell lines. Hurta RA; Wright JA Biochem Cell Biol; 1991 Sep; 69(9):635-42. PubMed ID: 1793565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]